You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 5, 2025

Claims for Patent: 8,399,469

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,399,469

Title:	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract:	The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Inventor(s):	Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Naruto, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Naruto, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Naruto, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Naruto, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Tokushima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo, JP)
Application Number:	11/790,604
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,399,469
Patent Claims:	1. Hydrate A of aripiprazole characterized by one or more of the properties chosen from: a powder x-ray diffraction spectrum comprising characteristic peaks at 20=12.6.degree. , 15.4.degree. , 17.3.degree. , 18.0.degree. , 18.6.degree. , 22.5.degree. and 24.8.degree. using a Cu K.sub..alpha.x-ray; an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 and 784 cm.sup.-1 on the IR (KBr) spectrum; and an endothermic trace comprising an endothermic peak at about 71.degree. C. and a second endothermic peak around 60.degree. C. to 120.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C/min). 2. Hydrate A of aripiprazole according to claim 1, wherein said Hydrate has a mean particle size of 50 .mu.m or less. 3. Hydrate A of aripiprazole accoding to claim 2, wherein said Hydrate has a mean particle size range of 36 to 14 .mu.m. 4. A process for preparing Hydrate A of aripiprazole wherein said process comprises milling Aripiprazole Hydrate characterized by one or more of the properties chosen from: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12. 6.degree. , 15.1.degree. , 17.4.degree. , 18.2.degree. , 18.7.degree. , 24.8.degree. and 27.5.degree. using a Cu K.sub..alpha.x-ray; and an endothermic trace comprising endothermic peaks at 75.0.degree. C., 123.5.degree. C. and 140. 5.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) to a mean particle size of 50 .mu.m or less. 5. A process according to claim 4, wherein said milling is performed by an atomizer using a rotational speed of 5000-15000 rpm for the main axis, a feed rotation of 10-30 rpm and a screen hole size of 1-5 mm. 6. Hydrate A of aripiprazole made by a pocess comprising milling Aripiprazole Hydrate characterized by one or more of the properties chosen from: a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree. , 15.1.degree. , 17.4.degree. , 18.2.degree. , 18.7.degree. , 24.8.degree. and 27.5.degree. using a Cu K.sub..alpha.x-ray; and an endothermic trace comprising endothermic peaks at 75.0.degree. C., 123.5.degree. C. and 140. 5.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C/min) to a mean particle size of 50 .mu.m or less. 7. Hydrate A of aripiprazole according to claim 6, wherein said milling is performed by an atomizer using a rotational speed of 5000-15000 rpm for the main axis, a feed rotation of 10-30 rpm and a screen hole size of 1-5 mm. 8. Hydrate A of aripiprazole according to claim 2, wherein said hydrate has a mean particle size of 20 .mu.m or less. 9. Hydrate A of aripiprazole according to claim 2, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 10. Hydrate A of aripiprazole according to claim 3, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 11. Hydrate A of aripiprazole according to claim 8, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 12. The process according to claim 4, wherein the Hydrate A of aripiprazole is characterized by one or more properties chosen from: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree. , 15.4.degree. , 17.3.degree. , 18.0.degree. , 18.6.degree. , 22.5.degree. and 24.8.degree. using a Cu K.sub..theta.x-ray; an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 and 784 cm.sup.-1 on the IR (KBr) spectrum; an endothermic trace comprising an endothermic peak at about 71.degree. C. and a second endothermic peak around 60.degree. C. to 120.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 520 C./min); and a mean particle size of 50 .mu.m or less. 13. Hydrate A of aripiprazole according to claim 6, wherein the Hydrate A of aripiprazole is characterized by one or more properties chosen from: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree. , 15.4.degree. , 17.3.degree. , 18.0.degree. , 18.6.degree. , 22.5.degree. and 24.8.degree. using a Cu K.sub..alpha.x-ray; an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 and 784 cm.sup.-1 on the IR (KBr) spectrum; an endothermic trace comprising an endothermic peak at about 71.degree. C. and a second endothermic peak around 60.degree. C. to 120.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min); and a mean particle size of 50 .mu.m or less. 14. Hydrate A of aripiprazole according to any one of claims 9, 10, or 11, wherein the mean particle size is measured by suspending 0.1 g of the Hydrate A of aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin. 15. Hydrate A of aripiprazole according to any one of claims 6, 7, or 13, wherein the mean particle size is measured by suspending 0.1 g of the Hydrate A of aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin using a laser diffraction particle size analyzer. 16. The process according to any one of claim 4 or 12, wherein the mean particle size is measured by suspending 0.1 g of the Hydrate A of aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin using a laser diffraction particle size analyzer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.